XOMA Royalty (NASDAQ:XOMA) (NASDAQ:XOMA) is a life sciences royalty company that specializes in acquiring and managing royalty interests in biopharmaceutical products and development-stage programs. The company generates revenue through milestone payments and royalty streams from partnered and commercial-stage drugs, providing investors with exposure to the growth of late‐stage therapeutic assets without the development risk and capital requirements associated with traditional biotech companies. XOMA Royalty focuses on high‐value assets targeting significant unmet medical needs, spanning cardiovascular, oncology, and neurology indications.
Since its launch, XOMA Royalty has built a diversified portfolio of royalty interests in both marketed and pipeline assets. Key holdings include royalties on mavacamten, a cardiac myosin inhibitor for obstructive hypertrophic cardiomyopathy, as well as interests in early‐stage immuno‐oncology and rare disease programs. The company pursues a disciplined approach to portfolio construction, seeking assets with validated clinical proof‐of‐concept or anticipated near‐term regulatory milestones. Geographically, its royalties derive primarily from sales in North America and Europe, with selective exposure to Asia Pacific markets through collaboration agreements and sub‐licensing partners.
Founded in 2020 as a spin‐off from XOMA Corporation, XOMA Royalty was created to unlock the value of legacy and newly acquired biopharmaceutical royalties. The company has since grown its royalty holdings through both exclusive negotiations with emerging biotech firms and strategic secondary market purchases. By partnering with research organizations and pharmaceutical companies, XOMA Royalty provides non‐dilutive capital that supports continued clinical development and commercialization activities, while banking on the long‐term success of the underlying therapies.
XOMA Royalty is led by a management team with deep expertise in biopharmaceutical development, royalty financing, and capital markets. The board and executive leadership combine technical know‐how with transaction experience, enabling the firm to identify attractive royalty opportunities and structure deals that balance risk and reward. With a streamlined operating model and a focus on yield generation, XOMA Royalty aims to deliver predictable, long‐term returns for shareholders while supporting the advancement of innovative therapies worldwide.
